Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Free Report) (TSE:I)’s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.06 and traded as high as $0.09. Intellipharmaceutics International shares last traded at $0.08, with a volume of 4,530 shares trading hands.
Intellipharmaceutics International Trading Up 12.7 %
The stock has a market capitalization of $2.61 million, a PE ratio of -0.72 and a beta of 1.57. The firm’s fifty day moving average price is $0.07 and its two-hundred day moving average price is $0.06.
Intellipharmaceutics International (OTCMKTS:IPCIF – Get Free Report) (TSE:I) last announced its earnings results on Tuesday, June 6th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.33 million for the quarter.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Read More
- Five stocks we like better than Intellipharmaceutics International
- What is a Special Dividend?
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- When to Sell a Stock for Profit or Loss
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- How to Invest in Fertilizer
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.